Emerald Advisers LLC Boosts Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Emerald Advisers LLC boosted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 826,475 shares of the specialty pharmaceutical company's stock after purchasing an additional 14,795 shares during the quarter. Emerald Advisers LLC owned approximately 2.57% of Collegium Pharmaceutical worth $24,670,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $2,432,000. Amundi grew its position in shares of Collegium Pharmaceutical by 188.3% during the 4th quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock worth $446,000 after buying an additional 10,168 shares in the last quarter. Vestcor Inc boosted its position in Collegium Pharmaceutical by 540.6% during the fourth quarter. Vestcor Inc now owns 16,578 shares of the specialty pharmaceutical company's stock valued at $475,000 after purchasing an additional 13,990 shares in the last quarter. Royce & Associates LP boosted its position in Collegium Pharmaceutical by 11.0% during the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after purchasing an additional 33,674 shares in the last quarter. Finally, Gallacher Capital Management LLC boosted its position in Collegium Pharmaceutical by 3.3% during the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company's stock valued at $417,000 after purchasing an additional 470 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on COLL. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Wall Street Zen cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $43.75.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the completion of the transaction, the director directly owned 70,658 shares of the company's stock, valued at approximately $2,163,547.96. The trade was a 8.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded down $0.23 during trading on Wednesday, hitting $31.77. The stock had a trading volume of 326,829 shares, compared to its average volume of 399,331. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 26.04 and a beta of 0.64. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The stock has a 50-day simple moving average of $29.90 and a two-hundred day simple moving average of $29.64.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The company had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. During the same period in the previous year, the firm posted $1.45 earnings per share. The company's revenue was up 22.7% compared to the same quarter last year. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical announced that its board has approved a share buyback plan on Monday, July 7th that allows the company to repurchase $150.00 million in shares. This repurchase authorization allows the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.